
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Barcelona, Spain - A systematic approach is best when investigating patients who report itch but have no rash, according to Joanna Wallengren, M.D., Ph.D., associate professor in the department of dermatology, University Hospital in Lund, Sweden. Dr. Wallengren described her approach to this at the 12th Congress of the European Academy of Dermatology and Venereology here.






